Song Zhiqiang, Zhou Yi, Wang Binbin, Geng Yuke, Tang Gusheng, Wang Yang, Yang Jianmin
Department of Hematology, Institute of Hematology, Shanghai Changhai Hospital, Naval Medical University, Shanghai 200433, China.
Department of Hematology, Myeloma & Lymphoma Center, Shanghai Changzheng Hospital, Naval Medical University, Shanghai 200433, China.
Genes Dis. 2025 Mar 25;12(6):101612. doi: 10.1016/j.gendis.2025.101612. eCollection 2025 Nov.
Chimeric antigen receptor T (CAR T) cell therapy has achieved remarkable efficacy for patients with hematological malignancies. However, viral vector-mediated production of CAR T cells is time-consuming and expensive and impairs T cell function. On one hand, an elaborate manufacturing process not only impairs the function of CAR T cells but also limits its usage in patients with rapidly progressing diseases. On the other hand, high costs are incompatible with broad clinical applications for sizable populations. production of CAR T cells is a novel approach that can avoid complicated production processes and reduce costs through mass production. Additionally, production of CAR T cells does not damage the function of T cells compared with production. Early studies have demonstrated promising antitumor activity of CAR T cell therapy in preclinical models of hematological malignancies. In this review, we describe the latest developments of CAR T cell therapy and discuss its potential challenges for clinical application.
嵌合抗原受体T（CAR T）细胞疗法已在血液系统恶性肿瘤患者中取得了显著疗效。然而，病毒载体介导的CAR T细胞生产耗时且昂贵，还会损害T细胞功能。一方面，复杂的生产过程不仅会损害CAR T细胞的功能，还限制了其在疾病快速进展患者中的应用。另一方面，高成本与大规模人群的广泛临床应用不相容。CAR T细胞的[此处原文缺失关键信息，无法准确翻译]生产是一种新方法，可避免复杂的生产过程并通过大规模生产降低成本。此外，与[此处原文缺失关键信息，无法准确翻译]生产相比，CAR T细胞的[此处原文缺失关键信息，无法准确翻译]生产不会损害T细胞功能。早期研究已在血液系统恶性肿瘤的临床前模型中证明了CAR T细胞疗法具有有前景的抗肿瘤活性。在本综述中，我们描述了CAR T细胞疗法的最新进展，并讨论了其临床应用的潜在挑战。
Zotero 插件
